Recently, a HER3-targeting affibody molecule was labeled with 89Zr and used to detect changes in HER3 expression in response to treatment of breast cancer xenografts with an HSP90 inhibitor [22]. The gene discussed is ERBB3; the disease is breast carcinoma.